BRPI1009346A2 - metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit - Google Patents

metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit

Info

Publication number
BRPI1009346A2
BRPI1009346A2 BRPI1009346A BRPI1009346A BRPI1009346A2 BR PI1009346 A2 BRPI1009346 A2 BR PI1009346A2 BR PI1009346 A BRPI1009346 A BR PI1009346A BR PI1009346 A BRPI1009346 A BR PI1009346A BR PI1009346 A2 BRPI1009346 A2 BR PI1009346A2
Authority
BR
Brazil
Prior art keywords
tumor
kit
optical
pharmaceutical composition
contrast agent
Prior art date
Application number
BRPI1009346A
Other languages
English (en)
Portuguese (pt)
Inventor
Sood Anup
Duh-Lan Lee Brian
William Castle Jason
Michael Fish Kenneth
Anne Staples Natalie
Lee Carter Randall
Original Assignee
General Eletric Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Eletric Company filed Critical General Eletric Company
Publication of BRPI1009346A2 publication Critical patent/BRPI1009346A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI1009346A 2009-03-19 2010-03-19 metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit BRPI1009346A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16153509P 2009-03-19 2009-03-19
PCT/EP2010/053619 WO2010106169A1 (en) 2009-03-19 2010-03-19 Optical imaging agents

Publications (1)

Publication Number Publication Date
BRPI1009346A2 true BRPI1009346A2 (pt) 2017-05-30

Family

ID=42331047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009346A BRPI1009346A2 (pt) 2009-03-19 2010-03-19 metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit

Country Status (11)

Country Link
US (1) US20120114563A1 (OSRAM)
EP (1) EP2413976A1 (OSRAM)
JP (1) JP2012520856A (OSRAM)
KR (1) KR20110138246A (OSRAM)
CN (1) CN102438659A (OSRAM)
AU (1) AU2010224789A1 (OSRAM)
BR (1) BRPI1009346A2 (OSRAM)
CA (1) CA2755770A1 (OSRAM)
MX (1) MX2011009808A (OSRAM)
RU (1) RU2011138096A (OSRAM)
WO (1) WO2010106169A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201015806D0 (en) 2010-09-21 2010-10-27 Ge Healthcare As Vascular imaging agents
WO2012088007A1 (en) 2010-12-21 2012-06-28 Pierce Biotechnology, Inc. Fluorescent compounds
US8889884B1 (en) 2011-07-14 2014-11-18 Pierce Biotechnology, Inc. Phosphine derivatives of fluorescent compounds
DK2736533T3 (en) 2011-07-29 2018-08-06 Avelas Biosciences Inc SELECTIVE SUBMISSION MOLECULES AND METHODS OF USE
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
US9751868B2 (en) 2012-02-28 2017-09-05 Pierce Biotechnology, Inc. Benzocyanine compounds
US20140072515A9 (en) 2012-03-02 2014-03-13 Greg Hermanson Cyanine compounds
JP6288970B2 (ja) * 2012-07-20 2018-03-07 キヤノン株式会社 化合物、および、前記化合物を有する光音響イメージング用造影剤
CN104470546B (zh) * 2012-07-20 2018-02-27 佳能株式会社 化合物和含有所述化合物的光声成像造影剂
WO2014035712A1 (en) 2012-08-28 2014-03-06 Pierce Biotechnology, Inc. Benzopyrylium compounds
WO2014055253A1 (en) * 2012-10-04 2014-04-10 The General Hospital Corporation Methods of synthesizing and using peg-like fluorochromes
WO2014115206A1 (ja) * 2013-01-28 2014-07-31 独立行政法人科学技術振興機構 組織透明化方法、組織透明化試薬及び組織観察方法
CN105102484B (zh) 2013-01-30 2020-03-10 艾维拉斯生物科学公司 选择性递送分子及使用方法
FR3001463B1 (fr) * 2013-01-31 2015-02-20 Commissariat Energie Atomique Particules luminescentes de carbone, procede de preparation et utilisation
WO2015105549A2 (en) * 2013-10-02 2015-07-16 University Of Massachusetts Surface functionalized, host-guest polymer nano-assemblies and methods thereof
US9416276B2 (en) 2013-11-07 2016-08-16 Canon Kabushiki Kaisha Method for producing contrast agent
US10245329B2 (en) 2014-09-08 2019-04-02 Canon Kabushiki Kaisha Composition having dye and conjugate of polyethyleneglycol and additive and contrast agent for photoacoustic imaging having the same
WO2016060277A1 (en) 2014-10-16 2016-04-21 Canon Kabushiki Kaisha Polymer, and contrast agent for photoacoustic imaging, including the polymer
US10398788B2 (en) 2014-10-24 2019-09-03 Canon Kabushiki Kaisha Polymer and contrast agent for photoacoustic imaging including the polymer
JP6700750B2 (ja) 2014-12-09 2020-05-27 キヤノン株式会社 化合物、および、前記化合物を有する光学イメージング用造影剤
WO2016097317A1 (en) 2014-12-19 2016-06-23 Bracco Imaging Spa Intra-operative imaging
WO2016111915A1 (en) * 2015-01-06 2016-07-14 De Haas Anthony H Near-infrared fluorescent surgical dye markers
JP2017002000A (ja) * 2015-06-12 2017-01-05 キヤノン株式会社 化合物又はその薬学的に受容可能な塩、及び、前記化合物又はその薬学的に受容可能な塩を有する光音響イメージング用造影剤。
WO2017057653A1 (en) 2015-09-30 2017-04-06 Canon Kabushiki Kaisha Conjugate of polysarcosine and nir contrast agent for photoacoustic imaging
JP6789636B2 (ja) 2015-09-30 2020-11-25 キヤノン株式会社 重合体、前記重合体を有する光音響イメージング用造影剤
CN105688230B (zh) * 2016-02-02 2018-12-11 史春梦 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用
CN109054013A (zh) * 2018-08-22 2018-12-21 东北大学 一种经修饰的吲哚菁绿及其制备方法
CN109738387A (zh) * 2018-12-29 2019-05-10 佛山科学技术学院 一种基于吲哚箐绿的光学相干层析成像方法和装置
WO2025197935A1 (ja) * 2024-03-19 2025-09-25 国立大学法人 東京大学 薬物－ポリマー複合体、医薬組成物、および薬物送達用ポリマー

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622685A (en) 1990-05-30 1997-04-22 Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts Polyether-substituted porphyrin anti-tumor agents
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
DE69820867T2 (de) 1997-04-29 2004-11-18 Amersham Health As Lichtbilderzeugungskontrastmitteln
GB2337523A (en) * 1998-04-29 1999-11-24 Nycomed Imaging As Light imaging contrast agents
US20100143258A1 (en) * 2008-12-05 2010-06-10 General Electric Company Tumor margin imaging agents

Also Published As

Publication number Publication date
MX2011009808A (es) 2011-09-30
EP2413976A1 (en) 2012-02-08
US20120114563A1 (en) 2012-05-10
CA2755770A1 (en) 2010-09-23
JP2012520856A (ja) 2012-09-10
AU2010224789A1 (en) 2011-10-06
RU2011138096A (ru) 2013-04-27
CN102438659A (zh) 2012-05-02
WO2010106169A1 (en) 2010-09-23
KR20110138246A (ko) 2011-12-26

Similar Documents

Publication Publication Date Title
BRPI0920030A2 (pt) agente de oclusão do tecido
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
EP2328630A4 (en) IN VIVO BIODEGRADABLE MEDICAL IMPLANT
DK2268317T3 (da) Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
PL2371385T3 (pl) Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0908143A2 (pt) Agente de branqueamento e preparação externa da pele
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
BRPI0716592A2 (pt) Composição para cuidado da pele
BRPI0719929A2 (pt) Partículas que compreendem um siloxano fluorado e métodos de preparo e uso das mesmas
BRPI0908361A2 (pt) Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição.
BRPI0822220A2 (pt) Composições contendo enzima e agente de matiz para tecidos
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
IL234064B (en) A therapeutic combination comprising trastuzumab-mcc-dm1 and docetaxel for use in the treatment of a cancer expressing erbb2
HRP20130382T1 (hr) Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
BRPI0910874A2 (pt) composições e métodos para cuidado da pele
BR112013015796A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
EP2292231A4 (en) MEDICAMENT FOR TREATING SPINAL STENOSIS
BRPI0917478A8 (pt) uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
DK2313404T3 (da) Quinuclidin-carbonat-derivater og medicinsk sammensætning deraf
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]